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ABSTRACT
A comparative evaluation of 384 selected sera was performed using the Beckman Coulter Access and
Abbott Axsym Toxo-IgG assays. The Axsym assay yields positive early results following infection, while
the Access assay gives higher titres during chronic infection. The ratio between the two complementary
tests, Axsym Toxo-IgG ⁄Access Toxo-IgG (Ax ⁄Ac), was compared with the Vidas anti-Toxoplasma IgG
avidity index (AI). The Ax ⁄Ac ratio decreased progressively as the time between infection and sampling
increased. The mean Ax ⁄Ac values (±SE) were 2.50 (±0.26), 2.14 (±0.13), 2.33 (±0.22), 1.34 (±0.09), 1.32
(±0.10), 0.92 (±0.08) and 0.74 (±0.07) for groups of sera sampled at 1, 2, 3, 4–5, 6–8, 9–12 and
13–24 months, respectively, after infection in pregnant women. These values were much smaller for
cases with chronic infection (>24 months), i.e., 0.56 (±0.03), 0.44 (±0.04) and 0.53 (±0.04), respectively, for
pregnant women and immunodepressed patients with and without reactivation. Taking a ratio of 1 as a
threshold for recent infection, the patients in the groups sampled at 1, 2 and 3 months had Ax ⁄Ac ratios
>1 in 49 ⁄ 50 (98%), 53 ⁄ 55 (96.4%) and 36 ⁄ 36 (100%) cases, respectively. Thus, an Ax ⁄Ac ratio of <1 in
serum from a pregnant woman allows a recent infection (<3 months) to be excluded. This technique has
the advantage of yielding positive results that develop much more rapidly than the AI, thereby helping
to reassure large numbers of pregnant women and avoiding costly and unnecessary prophylactic
treatment and follow-up.
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INTRODUCTION
The follow-up of obstetrical toxoplasmosis
depends mainly on the detection of anti-Toxo-
plasma-speciﬁc IgM and IgG [1–3]. When an
individual is positive for both IgM and IgG in
the absence of a previously diagnosed infection,
complementary tests are required to differenti-
ate between a recently acquired infection
(<3 months) and a more chronic infection. Such
tests include the detection of speciﬁc IgA and
IgE antibodies [4,5], but the avidity index (AI), a
technique developed about 15 years ago [6], is
the test used most widely [1–3]. An elevated AI
in the ﬁrst trimester of pregnancy excludes a
recent infection and helps to prevent unneces-
sary follow-up and treatment. Different tech-
niques to measure the AI in pregnancy have
been developed, evaluated and compared in a
number of studies [5,7–16]. Although the AI has
been universally accepted as a reliable test,
recent studies [10,11,16] have shown that the
evolution of a positive reaction is slow, so that
its use for excluding infections that have
occurred only a few months before pregnancy
is limited. Using 271 sera, it was recently
demonstrated that an avidity threshold of 0.2
was reached 6–24 months after infection (mean
11.49 ± 3.9 months), and that the avidity thresh-
old of 0.3 was reached 7 - >24 months after
infection (mean 14.20 ± 4.8 months) [10]. This
slow evolution of positive results, which varies
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according to the technique used for detection, is
the principal limitation of this test and justiﬁes
the use of complementary assays [16].
Another dating technique that compares the
results of two serological tests with different
antigenic targets (i.e., predominantly membra-
nous antigen and predominantly cytoplasmic
antigen) has also been studied with a view to
differentiating recent and chronic infection
[17,18]. One approach involves comparing the
kinetics of two commercially available assays in
parallel, e.g., the Axsym Toxo-IgG assay (Abbot
Diagnostic, Rungis, France) and the Assess
Toxo-IgG assay (Beckman Coulter, Roissy,
France). The principles and the techniques of
these two automated tests are very similar.
Axsym Toxo-IgG uses a microparticle enzyme
immunoassay, while Access Toxo-IgG uses a
chemiluminescence immunoassay with micro-
particles, and both use a two-step indirect
antibody test. Axsym Toxo-IgG seems to
become IgG-positive earlier, and gives sig-
niﬁcantly elevated IgG titres, compared
with Access Toxo-IgG, with sera taken in the
ﬁrst 3 months after infection. The present study
used 384 selected sera to compare these two
commercial immunoassays in terms of their
sensitivity and speed in detecting acute and
chronic infection, and also investigated the use
of the Axsym Toxo-IgG ⁄Access Toxo-IgG
(Ax ⁄Ac) ratio as a new technique for dating
toxoplasmosis infection. The kinetics of this
ratio and its correlation with the time after
infection were evaluated and compared with the
kinetics of the AI.
MATERIALS AND METHODS
Follow-up of pregnant women and immunodepressed
patients
The majority of sera (304 ⁄ 384) were from pregnant women
with known dates of infection (part 1), and the remainder
(80 ⁄ 384) were from cases of chronic toxoplasmosis with known
seroconversions >24 months previously (part 2), during the
period July 1998 to July 2005. All samples were stored at )20C
before investigation.
Part 1 of the study included 79 pregnant women with
seroconversion. The mean age at the time of seroconversion
was 28.8 ± 4.9 years (range 16–39 years). Clinical follow-up of
the pregnant women and their neonates was continued for up
to 1 year for 65 of these women. This group included 23 infants
who were born with congenital toxoplasmosis, and 43 infants
(including one pair of twins) who did not acquire the disease
(Table 1). The 304 sera were obtained from the 79 pregnant
women at 1–24 months after infection, and were divided into
seven equal sample groups on the basis of the interval between
sampling and infection (1, 2, 3, 4–5, 6–8, 9–12 and
13–24 months (±15 days).
It was possible to date infections because of the obligatory
monthly serological screening policy in France. Dating was
based on the following serological kinetic criteria. The ﬁrst
IgM-positive (or doubtful) serum according to the ISAgA assay
(bioMe´rieux, Durham, NC, USA) or the Toxo-IgM Access
assay (Beckman Coulter), with or without IgG, was dated as
1 month (±15 days) after infection. If IgG was absent from the
ﬁrst serum (IgM-positive, IgG-negative), its presence (accord-
ing to the Access and Axsym Toxo-IgG) during the follow-up
period was obligatory for conﬁrming infection. It was neces-
sary for the interval between the ﬁrst positive serum (IgM with
or without IgG) and the preceding negative serum to be
>2 months for inclusion in the study. Using these dating
criteria, the decision to start treatment was made as follows: (i)
no treatment was given when diagnosis was made at delivery
or following spontaneous abortion (13 ⁄ 79 cases); or (ii)
treatment with spiramycin (9 MIU ⁄mL) was continued for a
minimum of 15 days (66 ⁄ 79 cases), with changes made as
necessary (pyrimethamine + sulfadiazine for 9 ⁄ 66 cases), as
described previously by Flori et al. [6].
Table 1. Characteristics of 79 pregnant women with seroconversion and their infants
Time of
maternal
infection
(WG)
Mothers Infants
No. of
seroconversions
No. treated
during pregnancy
No. lost to
follow-up before
1 year of age
No. with proven
maternofetal transmission Fetal and paediatric disease
)6–4 10 10 (100%) 2 ⁄ 10 (20%) 0 ⁄ 8 (0%) No cases
5–14 24 23 (96%) 6 ⁄ 25 (24%) (one pair of twins) 2 ⁄ 19 (11%) 1 spontaneous abortion
1 clinical infection
15–27 24 24 (100%) 4 ⁄ 24 (17%) 11 ⁄ 20 (55%) 3 terminations of pregnancy
2 clinical infectionsa
6 subclinical infections
28–40 21 9 (45%) 2 ⁄ 21 (10%) 10 ⁄ 19 (53%) 10 subclinical infections
Total 79 66 (84%) 14 ⁄ 80 (17.5%) 23 ⁄ 66 (35%) 1 spontaneous abortion
3 terminations of pregnancy
3 clinical infectionsa
16 subclinical infections
WG, week of gestation.
aCerebral calciﬁcations and ⁄ or chorioretinal scar without severe visual impairment at an age of 1 year.
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In part 2 of the study, samples from chronic cases of
toxoplasmosis with seroconversions >24 months previously
were investigated. These included 30 sera from 30 pregnant
women known to be immunised during their previous
pregnancy, 20 sera from 20 immunodepressed patients
(infected with human immunodeﬁciency virus or with organ
transplants) who had serological reactivation (two or more
increasing antibody titres), and 30 sera from 30 immuno-
depressed human immunodeﬁciency virus and organ trans-
plant patients without reactivation.
Serological tests
Toxoplasma-speciﬁc IgG was detected using two commercial
enzyme immunoassays (Access Toxo-IgG and Axsym Toxo-
IgG) and an in-house immunoﬂuorescent assay (IFA). For
the latter, a positive cut-off of 8 IU ⁄mL was determined
using international standards [19]. An intermediate zone of
4–8 IU ⁄mL was included because of the inter-reader subjec-
tivity of the IFA. For the two commercial assays, the
following values were considered negative, equivocal and
positive: Access Toxo-IgG, <4.0, 4.0–6.0 and >6.0 IU ⁄mL,
respectively, and Axsym Toxo-IgG, <2.0, 2.0–3.0 and
>3.0 IU ⁄mL, respectively, according to the manufacturers’
recommendations.
Toxoplasma-speciﬁc IgM was detected by enzyme immuno-
assay (Access Toxo-IgMII; Beckman Coulter), by an in-house
IFA [19] and by an immunosorbent agglutination assay (IgM
ISAgA; bioMe´rieux). The results obtained were quantitative
and were expressed in arbitrary units. The following titres
were considered negative, equivocal and positive: Access
Toxo-IgM, <0.80, 0.80–1.00 and >1.00 signal ⁄ cut-off,
respectively; IFA, <1 ⁄ 20, 1 ⁄ 20 and ‡1 ⁄ 40 inverse of dilution,
respectively; and ISAgA for obstetrical samples, £4+, 5+-8+,
and 9+ -12+, respectively.
The IgG avidity test was performed as described previously
by Pelloux et al. [14], using a commercial immunoenzymatic
kit (Vidas Toxo IgG Avidity Kit; bioMe´rieux) according to the
manufacturer’s instructions. This test was performed using the
fully automated Vidas machine, which also calculates and
interprets the results. The AI is the ratio of the signal in the test
sample washed with 6 M urea (which disrupts low-avidity
complexes) to that of a sample washed without 6 M urea, with
<0.20 indicating low avidity, 0.20–0.30 indicating borderline
avidity and >0.300 indicating high avidity. According to the
manufacturer, high avidity excludes the possibility of an
infection acquired during the 4-month period before the
sample was taken.
Ax ⁄Ac IgG ratios were calculated only when the titres
were equal to or higher than the positivity threshold for
each test, i.e., ‡3 IU ⁄mL for Axsym Toxo-IgG and ‡6 IU ⁄mL
for Access Toxo-IgG. When the titres were higher than the
last calibration point (>300 IU ⁄mL for Axsym Toxo-IgG;
>500 IU ⁄mL for Access Toxo-IgG), a 1:10 dilution was made
using serum from negative cord blood in order to obtain
quantiﬁable titres for determining the ratio. The values after
dilution were found to be reproducible for the two
tests after testing 20 diluted sera in duplicate (range after
dilution for Axsym Toxo-IgG was 16–252 IU ⁄mL; range after
dilution for Access Toxo-IgG was: 26–493 IU ⁄mL). The
mean coefﬁcient of variation of the Ax ⁄Ac IgG ratio was
6.2% (0–13.0%); the range of the 20 Ax ⁄Ac IgG ratios was
0.43–3.70.
Statistical analysis
Paired Student’s t-tests were used for comparing the mean
Axsym Toxo-IgG and Access Toxo-IgG values for each group
of patients (p <0.05 was considered signiﬁcant). Spearman’s
rank correlation test was used to determine the association
between the AI, the Ax ⁄Ac ratio, and the time elapsed between
infection and sampling. Statistical assessment of differences in
the mean number of months before reaching the threshold
level for the avidity test or for the Ax ⁄Ac ratio in the different
treatment groups was estimated by ANOVA (Fisher–Snedecor
test, with p <0.05 considered signiﬁcant).
RESULTS
Kinetics of Axsym and Access Toxo-IgG assays
For the cases in part 1 of the study, the kinetics
of IgG development were different for the two
techniques (Table 2); in the ﬁrst 3 months after
infection (acute phase), the IgG titres were
almost always higher with Axsym Toxo-IgG
Table 2. Comparison of the kinetics of the Access Toxo-IgG and the Axsym Toxo-IgG assays using 384 selected sera from
79 pregnant women and 80 immunodepressed patients
Time after infection
(months ± 15 days)
No.
of sera
Access Axsym Paired Student’s t-test
No. positive
Mean IgG,
IU ⁄mL (±SE) No. positive
Mean IgG,
IU ⁄mL (±SE)
Mean (Axsym–
Access) (±SE) t p value
Part 1
1 50 24a (48%) 10.6 (±1.7) 41a (82%) 29.0 (±5.5) )18.4 (±4.1) )4.45 <0.001
2 55 52 (95%) 95.6 (±17.1) 54 (98%) 183 (±28.9) )87.9 (±14.1) )6.25 <0.001
3 36 36 (100%) 211 (±36.8) 36 (100%) 422 (±67.1) )211 (±47.0) )4.49 <0.001
4–5 45 45 (100%) 295 (±67.5) 45 (100%) 299 (±56.5) )4.05 (±40.3) )0.1 0.92
6–8 41 36 (88%) 228 (±82.9) 41 (100%) 230 (±62.5) )2.35 (±41.2) )0.06 0.96
9–12 43 42 (98%) 225 (±74.9) 43 (100%) 142 (±39.4) 83.5 (±43.5) 1.92 0.06
13–24 34 34 (100%) 219 (±74.2) 34 (100%) 105 (±29.2) 114 (±46.6) 2.44 0.02
Part 2 (>24 months)
Pregnancy 30 30 (100%) 33.9 (±6.0) 28 (93%) 17.4 (±2.6) 16.5 (±3.7) 4.42 <0.001
ID, no reactivation 30 29 (97%) 26.9 (±4.7) 28 (93%) 12.3 (±1.8) 14.6 (±3.2) 4.62 <0.001
ID, reactivation 20 20 (100%) 912 (±340) 20 (100%) 325 (±101) 587 (±246) 2.40 0.03
ID, immunodepressed.
aChi-square test, p <0.001.
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than with Access Toxo-IgG (one exception with
three successive sera) (paired Student’s t-test,
p <0.001). Axsym Toxo-IgG thus gave higher
titres, and titres that were more often positive,
with 41 of the 50 sera in the 1-month group
being positive, compared with only 24 according
to Access Toxo-IgG (chi-square test, p <0.001).
This early detection of IgG by Axsym Toxo-IgG
allowed rapid conﬁrmation of the speciﬁcity of
the IgM titres. The tendency towards higher
titres according to Axsym Toxo-IgG levelled off
at 4–5 months after infection, and was then
progressively inverted (i.e., Access Toxo-IgG
titres were greater than Axsym Toxo-IgG titres)
for the 9–12-month and the 13–24-month groups
(paired Student’s t-test, p 0.02) (Table 2). More-
over, in part 2 of the study, involving cases of
chronic infection (>24 months), the IgG titres
according to Access Toxo-IgG were twice as high
for both pregnant women and immunodepressed
patients. This was even more so for 20 immu-
nodepressed cases with serological reactivation.
Among the 60 sera from individuals with
chronic infection and without reactivation (preg-
nant women and immunodepressed patients),
Axsym Toxo-IgG was negative for two sera
(<2 IU ⁄mL) and borderline for two others
(2–3 IU ⁄mL), whereas, with one exception
(5.3 IU ⁄mL), all had titres >6 IU ⁄mL according
to Access Toxo-IgG.
Evolution of the Ax ⁄Ac ratio as a function
of the interval between infection and sampling
It was possible to calculate the Ax ⁄Ac ratio even
when the results for both of these automated tests
were higher than the positivity threshold recom-
mended by the manufacturers. In the present
study, it was possible to determine this ratio for
263 of 304 sera taken from pregnant women who
had been followed-up for seroconversion, and for
76 of 80 sera taken from patients with chronic
infection. In comparison, it was possible to mea-
sure the AI for 256 of 304 and 76 of 80 sera,
respectively.
For the sera with accurately dated infections
(part 1), the mean Ax ⁄Ac ratios (±SE) were 2.50
(±0.26), 2.14 (±0.13), 2.33 (±0.22), 1.34 (±0.09), 1.32
(±0.10), 0.92 (±0.08), 0.74 (±0.07), respectively, for
sera taken at 1, 2, 3, 4–5, 6–8, 9–12 and
13–24 months after infection. For sera taken from
patients with chronic infection (>24 months;
part 2), the mean Ax ⁄Ac ratios were much lower,
being 0.56 (±0.03), 0.44 (±0.04) and 0.53 (±0.04) for
pregnant women and patients with immunode-
pression, with and without reactivation, respec-
tively.
Taking a ratio of 1 as the threshold (receiver
operator characteristic analysis; data not shown),
1 ⁄ 50 (2%), 2 ⁄ 55 (3.6%) and 0 ⁄ 36 (0%), respec-
tively, of the sera taken 1, 2 and 3 months after
infection had a ratio <1 (Table 3), with the three
sera yielding an Ax ⁄Ac ratio of <1 having been
taken from the same patient. Moreover, only 12
of 141 sera from these three groups had ratios
of 1–1.2 (threshold + 2 SE). In contrast, of the
sera taken from patients with chronic infection
(>24 months), 80 ⁄ 80 (100%) yielded an Ax ⁄Ac
ratio <1 (Table 3). The correlation between the
Ax ⁄Ac ratio and the time between infection and
sampling was signiﬁcant and inversely propor-
tional (r = )0.59; p <0.001) (Fig. 1).
Table 3. Comparison of the kinetics of mean Axsym Toxo-IgG ⁄Access Toxo-IgG ratios and mean Vidas Toxo-IgG avidity
index for 109 pregnant women and 50 immunodepressed patients
Time after infection
(months ± 15 days)
No.
of sera
Mean ratio
(Axsym Toxo-IgGM ⁄
Access Toxo-IgG) (±SE)
% with
ratio <1
Mean avidity
index (±SE)
% with avidity
index >0.3
Part 1
1 50 2.50 (±0.26) 2 0.032 (±0.003) 0
2 55 2.14 (±0.13) 3.6 0.050 (±0.005) 0
3 36 2.33 (±0.22) 0 0.071 (±0.007) 0
4–5 45 1.34 (±0.09) 26.6 0.098 (±0.009) 2.2
6–8 41 1.32 (±0.10) 34.1 0.143 (±0.016) 5
9–12 43 0.92 (±0.08) 59.5 0.27 (±0.017) 46.5
13–24 34 0.74 (±0.07) 82.3 0.32 (±0.017) 61.7
Part 2 (>24 months)
Pregnancy 30 0.56 (±0.03) 100 0.52 (±0.019) 96.7
ID, no reactivation 30 0.53 (±0.04) 100 0.52 (±0.022) 96.7
ID, reactivation 20 0.44 (±0.04) 100 0.60 (±0.013) 100
ID, immunodepressed.
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Evolution of the Ax ⁄Ac ratio as a function
of treatment
The inﬂuence of treatment on the kinetics of the
serological titres and the assay ratios was inves-
tigated. Prophylactic treatment (spiramycin alone
for >15 days) signiﬁcantly reduced the serological
titres according to both assays to a similar degree
(Table 4). In contrast, there was no signiﬁcant
difference in the kinetics of the Ax ⁄Ac ratios
between the treated and untreated patients
(p >0.2). For the non-treated pregnant women
who were diagnosed either at delivery or after a
spontaneous abortion (13 cases, 50 sera), the mean
Ax ⁄Ac ratios (±SE) were 2.49 (±0.55), 2.11 (±0.20),
2.32 (±0.45), 1.61 (±0.48), 1.64 (±0.36), 1.02 (±0.13)
and 0.88 (±0.29) for the sera taken 1, 2, 3, 4–5, 6–8,
9–12 and 13–24 months after infection, respec-
tively. These results were comparable to those for
the treated women (66 cases, 254 sera) with mean
Ax ⁄Ac ratios (±SE) of 2.60 (±0.29), 2.16 (±0.16),
2.33 (±0.25), 1.30 (±0.08), 1.25 (±0.10), 0.90 (±0.09)
and 0.74 (±0.08), respectively.
Comparison with the Toxo-IgG Avidity Vidas
assay
As with the Ax ⁄Ac ratio, there was a strong
correlation between the AI and the time between
infection and sampling (r = 0.90; p <0.001)
(Fig. 2). However, the kinetics of the AI were
slow, with an increase of c. 0.02 ⁄month in the ﬁrst
few months after infection (Table 3). The thresh-
old of 0.3 was rarely attained before 6 months
(1 ⁄ 45 sera for the 4–5-month group), whereas the
Ax ⁄Ac ratio decreased rapidly to below the
proposed threshold of 1 in a larger number of
cases (12 ⁄ 45 for the 4–5-month group). This
slower evolution of the AI, compared with the
Ax ⁄Ac ratio, was conﬁrmed for samples with
longer intervals between infection and sampling.
Whereas only 2 ⁄ 41 (5%), 20 ⁄ 43 (46.5%) and 21 ⁄ 34
(61.7%), respectively, of the sera from the 6–8-,
9–12- and 13–24-month groups attained an AI
threshold of 0.3, the Ax ⁄Ac ratio of <1 was
attained in 14 ⁄ 41 (34.1%), 26 ⁄ 43 (59.5%) and
28 ⁄ 34 (82.3%) of sera, respectively (Table 3).
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Fig. 1. Evolution of the Axsym
IgG ⁄Access IgG ratio, based on the
time between infection and sam-
pling, for 384 selected sera. Correla-
tion between the ratio and time
between infection and sampling
was r = )0.59 (p <0.001). The three
circled sera came from the same
pregnant woman. aPreg, pregnancy;
bID, immunodepressed; cID+React,
ID with reactivation.
Table 4. Comparison of the kinetics of the Access Toxo-IgG and the Axsym Toxo-IgG assays using 304 selected sera from
66 treated and 13 non-treated pregnant women
Time after
infection
(months ± 15 days)
Treateda Non-treatedb Access Toxo-IgG Axsym Toxo-IgG
No. of
sera
No.
of sera
Treateda
Mean IgG,
IU ⁄mL (±SE)
Non-treatedb
Mean IgG,
IU ⁄mL (±SE)
Student’s
t-test,
p
Treateda
Mean IgG,
IU ⁄mL (±SE)
Non-treatedb
Mean IgG,
IU ⁄mL (±SE)
Student’s
t-test,
p
1 43 7 10.5 (±1.8) 10.8 (±5.1) NS 28.5 (±5.8) 31.8 (±17.5) NS
2 41 14 75 (±13) 155 (±53) 0.02 150 (±27) 281 (±79) NS
3 28 8 168 (±31) 353 (±110) 0.04 334 (±56) 708 (±198) 0.02
4–5 40 5 232 (±60) 795 (±318) <0.01 218 (±37) 935 (±307) <0.01
6–8 35 6 106 (±28) 1234 (±785) <0.01 111 (±26) 889 (±268) <0.01
9–12 37 6 194 (±70) 416 (±321) NS 110 (±28) 337 (±220) 0.04
13–24 30 4 209 (±82) 294 (±125) NS 94 (±32) 190 (±59) NS
NS, not signiﬁcant.
aSpiramycin 9 MIU ⁄day for ‡15 days.
bNon-treated cases, diagnosis at delivery or at spontaneous abortion.
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DISCUSSION
Serological results that are positive for both IgM
and IgG are difﬁcult to interpret during the ﬁrst
trimester of pregnancy in the absence of a known
preceding Toxoplasma infection. This serological
proﬁle is relatively common, representing >1% of
the cases seen in our laboratory (data not shown).
This is related to the availability of increasingly
sensitive IgM detection techniques, which are able
to detect residual IgM >1 year after seroconver-
sion [5,20,21], and the relatively high prevalence
of toxoplasmosis in France of c. 50% [22]. How-
ever, even if this IgM+ and IgG+ proﬁle is a
warning sign, it is only rarely associated with an
acute infection at the onset of pregnancy. In such
cases, the AI is useful [1,3,16], in that it allows
recent infection to be excluded for >50% of the
cases (data not shown). The AI test is reliable and,
to our knowledge, with the exception of a recent
report concerning a particular Vidas Toxo-IgG IV
avidity assay [11], there have been no docu-
mented cases of seroconversion in <4 months that
were associated with an AI of >0.3. Globally, the
AI allows the exclusion of any risk of congenital
toxoplasmosis. However, the present study con-
ﬁrms previous reports that the AI evolves slowly
[10,11,16]. Among pregnant women presenting
with positive IgM and IgG and an AI of <0.3
(0.5% in our laboratory; data not shown), a large
number were probably infected before pregnancy,
and thus are not at risk of maternofetal transmis-
sion. For these cases, a possible solution would be
to decrease the AI threshold to 0.2 [10]. This
permits more women to be reassured without
introducing a signiﬁcant risk, since only one of
141 sera taken after 1, 2, and 3 months in the
present study had an AI >0.2 (i.e., 0.21).
An alternative approach could involve the
coupling and comparison of two serological
techniques that use different antigenic targets
[17,18]. In the present study, two automated tests,
Axsym Toxo-IgG and Access Toxo-IgG, were
compared. Axsym Toxo-IgG becomes positive
early, whereas Access Toxo-IgG allows an old
infection to be conﬁrmed with more assurance
(titres elevated two-fold). The early positivity of
Axsym Toxo-IgG assay has been described pre-
viously [23–26], and may be linked to the nature
of the antigen used by the manufacturer, which is
mainly membrane-associated [23]. The difference
in the kinetics of the two tests may be related to
the difference in the antigens used. Little infor-
mation is available concerning the exact compo-
sition and preparation method of the antigens
used in these assays, but there are only minor
technical differences between the two tests.
Axsym Toxo-IgG uses latex microbeads, whereas
Access Toxo-IgG uses polyethylene microbeads
covered with metallic oxide (paramagnetic
beads). The diameters of the microparticles used
in the two tests are also very similar (0.5–1 lm).
Based on the results obtained, it is proposed
that the ratio of Axsym Toxo-IgG and Access
Toxo-IgG can be used as an additional test for
dating toxoplasmosis. It is important to note that
treatment reduces the titres obtained with both
techniques to a similar degree, but does not
modify the ratio between the two tests (Table 4).
In all cases, the ratio was high during the ﬁrst
3 months of infection, and then decreased with
time. This ratio has the advantage of developing
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Fig. 2. Evolution of the Toxo-IgG
avidity Vidas results, based on the
time between infection and sam-
pling, for 384 selected sera. Correla-
tion between Toxo-IgG avidity index
and time between infection and
sampling: r = 0.90 (p <0.001). aPreg,
pregnancy; bID, immunodepressed;
cID+React, ID with reactivation.
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much more rapidly than the AI, but does not
guarantee 100% exclusion. Thus, three and 15 of
the 141 sera taken after 1, 2 and 3 months had
abnormally low ratios of <1 (the proposed thresh-
old) and <1.20 (threshold + 2 SE), respectively
(Fig. 1). However, all three sera with an Ax ⁄Ac
ratio of <1 were from the same patient, and ten of
the 15 sera with Ax ⁄Ac ratios <1.2 had very low
serological titres of <30 IU ⁄mL. The Ax ⁄Ac ratio
must therefore be interpreted with caution for
sera with titres <30 IU ⁄mL. Nevertheless, it is
suggested that the Ax ⁄Ac ratio can be used as a
second-line exclusion test for cases with an AI of
<0.3 in the ﬁrst trimester of pregnancy (Fig. 3).
This test is applicable when Axsym Toxo-IgG and
Access Toxo-IgG both indicate >30 IU ⁄mL. In
such cases an Ax ⁄Ac ratio of <1 allows the
possibility of a recent infection within the previ-
ous 3 months to be excluded. In the absence of
seroconversion studies with a much larger cohort,
a further serological control is necessary after
10 days for cases presenting with IgM+, IgG+,
AI <0.3 and an Ax ⁄Ac ratio <1 in order to conﬁrm
the absence of a rise in serological titres (Fig. 3).
This new approach to dating Toxoplasma infec-
tion presents the following advantages: (i) opti-
misation of the technique is simple and it could be
performed in many laboratories; (ii) similar
results might be obtained by comparing other
serological assays, provided that one assay
detects IgG maturation earlier than the other;
(iii) the approach could be developed commer-
cially so that two tests could be performed using
the same automated machine; and (iv) as with the
avidity test, it is possible to date infection at the
onset of pregnancy with the ﬁrst sample, thereby
enabling the start of any necessary prophylactic
treatment without waiting for a second sample,
while at the same time allowing the exclusion of
recent infection occurring within 3 months of the
onset of pregnancy. This will help to reassure
patients and prevent unnecessary and costly
prophylactic treatment and follow-up.
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